Overall Survival (OS) Impact for NSCLC Patients with irAE and Non-irAE Hospital Admissions During First line Pembrolizumab Treatment
07:30am - 03:35pm EST - April 5, 2024
07:30am - 03:35pm EST - April 5, 2024
Abstract: JNCCN23-0529 https://jnccn.org/view/journal...
Author(s):
- Adam Khorasanchi, MD, Hospitalist, The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute
Tags: Member Institution Clinical Oncology
| Display Label | Action |
|---|---|
| 036 - General Poster Session | Download Handout |
| AdamKhorasanchi_NCCN24_Poster.pdf | Download Handout |
| AC24P36 - Overall Survival (OS) Impact for NSCLC Patients with irAE and Non-irAE Hospital Admissions During First line Pembrolizumab Treatment | Download MP3 |